company background image
SILCOPHL logo

Silco Pharmaceuticals DSE:SILCOPHL Stock Report

Last Price

৳17.70

Market Cap

৳1.8b

7D

2.3%

1Y

-26.6%

Updated

22 Jun, 2024

Data

Company Financials

Silco Pharmaceuticals Limited

DSE:SILCOPHL Stock Report

Market Cap: ৳1.8b

SILCOPHL Stock Overview

Manufactures and markets finished pharmaceutical products in Bangladesh.

SILCOPHL fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends2/6

Silco Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Silco Pharmaceuticals
Historical stock prices
Current Share Price৳17.70
52 Week High৳25.20
52 Week Low৳16.20
Beta0.25
11 Month Change-5.85%
3 Month Change-8.76%
1 Year Change-26.56%
33 Year Change-32.95%
5 Year Change-22.12%
Change since IPO-22.43%

Recent News & Updates

Recent updates

Shareholder Returns

SILCOPHLBD PharmaceuticalsBD Market
7D2.3%4.2%3.2%
1Y-26.6%-20.8%-24.3%

Return vs Industry: SILCOPHL underperformed the BD Pharmaceuticals industry which returned -20.8% over the past year.

Return vs Market: SILCOPHL underperformed the BD Market which returned -24.3% over the past year.

Price Volatility

Is SILCOPHL's price volatile compared to industry and market?
SILCOPHL volatility
SILCOPHL Average Weekly Movement5.5%
Pharmaceuticals Industry Average Movement6.8%
Market Average Movement5.4%
10% most volatile stocks in BD Market7.6%
10% least volatile stocks in BD Market3.4%

Stable Share Price: SILCOPHL has not had significant price volatility in the past 3 months.

Volatility Over Time: SILCOPHL's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995311Md. Haque Rukanwww.silcopharma.com

Silco Pharmaceuticals Limited manufactures and markets finished pharmaceutical products in Bangladesh. The company offers products in the therapeutic areas of analgesic and antipyretic, anti-platelet, antiasthmatic, antibiotic, antidepressant, antidiabetic, antiemetic, antifungal, antihistamin, antihypertensive and antianginal, antimicrobial, antiprotozoal, antispasmodic, antiulcerant, anxiolytic, calcium and combinations, central muscle relaxants, diuretics, gastroprokinetic, haematinic, vitamins and minerals, laxatives, lipid lowering agents, mycolytic expectorants, and NSAIDs, as well as multi-medicines. It provides its products in various human drugs dosage forms, such as tablets, capsules, syrups, oral solids and liquids, suspension and powder for suspension, etc. The company also exports its medicines to Afghanistan, Bhutan, Myanmar, Ivory Coast, Kenya, Mauritius, Somalia, Tanzania, Uganda, and internationally.

Silco Pharmaceuticals Limited Fundamentals Summary

How do Silco Pharmaceuticals's earnings and revenue compare to its market cap?
SILCOPHL fundamental statistics
Market cap৳1.84b
Earnings (TTM)৳42.76m
Revenue (TTM)৳421.83m

43.0x

P/E Ratio

4.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SILCOPHL income statement (TTM)
Revenue৳421.83m
Cost of Revenue৳295.37m
Gross Profit৳126.47m
Other Expenses৳83.71m
Earnings৳42.76m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.41
Gross Margin29.98%
Net Profit Margin10.14%
Debt/Equity Ratio0%

How did SILCOPHL perform over the long term?

See historical performance and comparison

Dividends

1.7%

Current Dividend Yield

66%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.